Integration of Breast Reconstruction and Radiation: How the Proton-Photon Debate Exposes Methodological Gaps, Analytical Bias, and Lack of Consensus.

For breast cancer patients undergoing mastectomy and reconstruction, postmastectomy radiation therapy jeopardizes reconstruction outcomes, yet no universal consensus exists for integrating postmastectomy radiation therapy with breast reconstruction. The recent expansion of proton therapy has intensified a debate over its role in this setting. Although protons offer superior dosimetry and cardiac sparing compared to photons, several studies, focusing on implant-based reconstruction, report higher rates of capsular contracture and reconstruction failure with protons, whereas others show comparable protons outcomes to photons. These discordant findings reveal not only questions about radiation modality but also deeper flaws in the reconstruction literature-heterogeneous inclusion criteria, inconsistent endpoint definitions, reliance on historical controls, and inadequate adjustment for surgical confounders. Such methodological weaknesses have tangible consequences: policy decisions (eg, payer coverage for proton therapy) may be based on incomparable outcomes; patient counseling becomes inconsistent, with surgeons and radiation oncologists quoting different risks; and trial design suffers, as discordant rates affect sample size calculations. In this review, we use the proton-photon debate as a lens to expose how inconsistent reporting and research methodological weaknesses in the field of breast reconstruction have hindered reaching a consensus. We advocate for methodological standardization through harmonized endpoints definitions and stratified cohort design. Establishing reporting frameworks that integrate surgical events and patient-reported outcomes is essential to generate interpretable evidence, inform reimbursement policy, and align practices across radiation oncology and reconstructive surgery fields.